9th IPF Summit

The pulmonary fibrosis field is entering a pivotal moment. Boehringer Ingelheim’s positive Phase 3 trials for nerandomilast, poised to be the first new approval in over a decade, have injected long-awaited momentum into the space. PureTech Health, Endeavor BioMedicines, Insilico Medicine, Bristol Myers Squibb, and United Therapeutics are rapidly advancing through mid- to late-stage trials, signaling a renewed era of therapeutic possibility. Yet 2025 has also brought setbacks, including Pliant’s discontinuation of the BEACON-IPF study for bexotegrast due to safety concerns, underscoring the complexity of treating this disease. If ever there was a year to invest in this space, it’s now. This August, meet your global community, spanning discovery, preclinical, translational, and clinical development, at the only industry-focused summit dedicated to pulmonary fibrosis. Gain the full spectrum of insight needed to bring better drugs to patients, faster. View the full agenda here: Speakers: Toby Maher, Professor of Clinical Medicine and Director of Interstitial Lung Disease, University of Southern California, Justin Oldham, Associate Professor, University of Michigan, Darrell Kotton, Professor of Medicine and Director of the Center for Regenerative Medicine (CReM), Boston University, Fernando Martinez, Early Chair in Biomedical Research, Pulmonary Medicine, University of Massachusetts Medical School, Mary Strek, Professor of Medicine CoDirector, Interstitial Lung Disease Clinic Director, Pulmonary Medicine Service, University of Chicago, Joyce Lee, Professor - Medicine Pulmonary Sciences and Critical Care, UCDHSC, Emilie Millaire, Respirologist, CIC Mauricie inc, Lorna Harries, Chief Scientific Officer and Founder, Senisca Ltd, Dori Thomas-Karyat, Chief Executive Officer, Synthis Therapeutics, Inc, Eugenia Ruiz, Chief Scientific Officer, GAT Therapeutics, Iris Alroy, Co-Founder and Scientific Chief and Officer, Anima Biotech, Robin Mansukhani, Chief Executive Officer, Deciduous Therapeutics, Brian Windsor, President and Chief Executive Officer, Rein Therapeutics, Marco Quarta, Co-Founder and Chief Scientific Officer, Rubedo Life Sciences, James Cassella, Chief Development Officer, Trevi Therapeutics, David Salzman, Founder and Chief Executive Officer, GATEHOUSE BIO, Jonas Hallén, Chief Medical Officer and Co-Founder, Calluna Pharma, Ahmed Mousa, Chief Executive Officer, Vicore Pharma Holding, Bertil Lindmark, Chief Medical Officer, Vicore Pharma Holding, Cory Hogaboam, Chief Scientific Officer, Rein Therapeutics, Marco Quarta, Co-Founder, Chief Scientific Officer and Board Member, Rubedo Life Sciences, Eric White, Senior Lead - Clinical Program and ILD, Boehringer Ingelheim, Carol Ann Satler, MD PhD Vice President - Clinical Development, Insilico Medicine, Susanne Stowasser, Head of Clinical Development and Medical Affairs - Pulmonology, Boehringer Ingelheim, Raghu Kumar Penke, Senior Scientist, Ionis Pharmaceuticals, Cara Williams, Vice President, Pfizer, Jalpa Patel, Scientific Director- Specialty Pipeline and Global Medical Affairs, Abbvie, Travis Barr, Principal Scientist - Biology Discovery - Cardio Metabolic Disease and Fibrosis Team, Merck and Co, Aditya Patel, Clinical Development Lead, Bristol Myers Squibb, Franck Rahaghi, Executive Director of Cardiopulmonary, Global Medical Affairs, United Therapeutics Corp., Min Lu, Executive Director - Biology, Eli Lilly and Co., Matthew Thomas, Department Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim, Billy Fahy, Executive Director - Early Clinical Research Programs and Respiratory Lead, GSK, Peter Schafer, Scientific Vice President and Head of Immunology, Cardiovascular, and Neuroscience Translational Medicine Disease Team, Bristol Myers Squibb, Chris Barnes, Vice President - Biometrics, Pliant Therapeutics Inc., Elizabeth Estes, Executive Director, OSIC ILD, Camilla Graham, Vice President, Medical Affairs, PureTech Health, Paul Ford, Independent Consultant, Former Chief Medical Officer of Galecto